Arthur F Ryan sold $95k of REGN
director at REGENERON PHARMACEUTICALS, INC.. 100 shares at an average of $954.22, traded Feb 1, 2024, filed Feb 5, 2024.
Score components
- +15RoleDirector
- +10Trade size$95k at market
- 0Share of holdings soldSold 0.5% of holdings
- +15Cluster9 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +3.8%, 3m +2.4%, 6m +14.4%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001968202-24-000048, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 1, 2024 | SOpen-market sale Common Stock10b5-1 | -1 | $939.53 | $940 | 18,481 | Feb 5, 2024 |
| Feb 1, 2024 | SOpen-market sale Common Stock10b5-1 | -6 | $941.91 | $5,651 | 18,475 | Feb 5, 2024 |
| Feb 1, 2024 | SOpen-market sale Common Stock10b5-1 | -5 | $942.50 | $4,713 | 18,470 | Feb 5, 2024 |
| Feb 1, 2024 | SOpen-market sale Common Stock10b5-1 | -3 | $943.54 | $2,831 | 18,467 | Feb 5, 2024 |
| Feb 1, 2024 | SOpen-market sale Common Stock10b5-1 | -1 | $944.66 | $945 | 18,466 | Feb 5, 2024 |
| Feb 1, 2024 | SOpen-market sale Common Stock10b5-1 | -3 | $947.37 | $2,842 | 18,463 | Feb 5, 2024 |
| Feb 1, 2024 | SOpen-market sale Common Stock10b5-1 | -1 | $948.77 | $949 | 18,462 | Feb 5, 2024 |
| Feb 1, 2024 | SOpen-market sale Common Stock10b5-1 | -10 | $949.48 | $9,495 | 18,452 | Feb 5, 2024 |
| Feb 1, 2024 | SOpen-market sale Common Stock10b5-1 | -2 | $950.01 | $1,900 | 18,450 | Feb 5, 2024 |
| Feb 1, 2024 | SOpen-market sale Common Stock10b5-1 | -3 | $951.40 | $2,854 | 18,447 | Feb 5, 2024 |
| Feb 1, 2024 | SOpen-market sale Common Stock10b5-1 | -3 | $953.18 | $2,860 | 18,444 | Feb 5, 2024 |
| Feb 1, 2024 | SOpen-market sale Common Stock10b5-1 | -5 | $954.52 | $4,773 | 18,439 | Feb 5, 2024 |
| Feb 1, 2024 | SOpen-market sale Common Stock10b5-1 | -10 | $955.35 | $9,554 | 18,429 | Feb 5, 2024 |
| Feb 1, 2024 | SOpen-market sale Common Stock10b5-1 | -7 | $956.21 | $6,693 | 18,422 | Feb 5, 2024 |
| Feb 1, 2024 | SOpen-market sale Common Stock10b5-1 | -3 | $957.75 | $2,873 | 18,419 | Feb 5, 2024 |
| Feb 1, 2024 | SOpen-market sale Common Stock10b5-1 | -5 | $958.65 | $4,793 | 18,414 | Feb 5, 2024 |
| Feb 1, 2024 | SOpen-market sale Common Stock10b5-1 | -8 | $959.68 | $7,677 | 18,406 | Feb 5, 2024 |
| Feb 1, 2024 | SOpen-market sale Common Stock10b5-1 | -10 | $960.52 | $9,605 | 18,396 | Feb 5, 2024 |
| Feb 1, 2024 | SOpen-market sale Common Stock10b5-1 | -4 | $961.37 | $3,845 | 18,392 | Feb 5, 2024 |
| Feb 1, 2024 | SOpen-market sale Common Stock10b5-1 | -6 | $962.49 | $5,775 | 18,386 | Feb 5, 2024 |
| Feb 1, 2024 | SOpen-market sale Common Stock10b5-1 | -4 | $963.73 | $3,855 | 18,382 | Feb 5, 2024 |
Related signals
Other insiders at REGENERON PHARMACEUTICALS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 13Weak | REGENERON PHARMACEUTICALS, INC. | Kathryn Guarini director | $340k 400 shares | -40% | |
| 33Weak | REGENERON PHARMACEUTICALS, INC. | Marion McCourt EVP Commercial | $2.0M 2,346 shares | -16% | |
| 12Weak | REGENERON PHARMACEUTICALS, INC. | Kathryn Guarini director | $320k 400 shares | -40% | |
| 18Weak | REGENERON PHARMACEUTICALS, INC. | Huda Y Zoghbi director | $640k 800 shares | -32% | |
| 6Weak | REGENERON PHARMACEUTICALS, INC. | Arthur F Ryan director | $130k 200 shares | -1% | |
| 3Weak | REGENERON PHARMACEUTICALS, INC. | Arthur F Ryan director | $71k 100 shares | -1% | |
| 4Weak | REGENERON PHARMACEUTICALS, INC. | Arthur F Ryan director | $78k 100 shares | -1% | |
| 12Weak | REGENERON PHARMACEUTICALS, INC. | Arthur F Ryan director | $79k 100 shares | -1% | |
| 30Weak | REGENERON PHARMACEUTICALS, INC. | Huda Y Zoghbi director | $1.3M 1,638 shares | -49% | |
| 30Weak | REGENERON PHARMACEUTICALS, INC. | Jason Pitofsky SVP Controller | $1.6M 2,036 shares | -32% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.